• Tel: +86 0571-85586753
  • Email: sales@fluoropharm.com
Structure Search
  • 中文版
Fluoropharm
  • About Us
    • Company Profile
    • Our Culture
    • Join Us
  • Products
    • Fluorinated API
    • Fluorinated pharmaceutical intermediates
    • Fluorinated fine chemicals
    • Other series
  • Technology service
  • News
  • Contact Us

Name Index H

Products Sitemap

  • Cas Index
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • Name Index
  • A
  • B
  •  
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Name Index H

Cat.No. Chemical Name MolFormula
OF16787 375-19-9 | Heptafluorobutyramidine C4H3F7N2
OF16398 161337-67-3 | Hafnium(IV) trifluoromethanesulphonate C4F12HfO12S4
OF14459 378-34-7 | Heptafluoroisopropylbenzene C9H7F7
OF11744 408-38-8 | Hexadecyl fluoride C16H33F
OF10946 780-87-0 | Heptafluoro-1-(trifluoromethyl)cyclopent-1-ene C6F10
OF10865 113612-30-9 | Heptafluoro-1-iodobut-1-ene C4F7I
OF10706 429-18-5 | Hexakis(1H,1H-perfluoropropoxy)phosphazene C18H12F30N3O6P3
OF10642 3830-74-8 | Hexakis(1H,1H,7H-perfluoroheptoxy)phosphazene C42H18F72N3O6P3
OF10259 16059-16-8 | Hexakis(1H,1H,5H-perfluoropentoxy)phosphazene C30H18F48N3O6P3
ZH10009 34202-69-2 | Hexafluoroacetone trihydrate C3F6O.3H2O
ZH10008 428-59-1 | Hexafluoropropylene oxide C3F6O
YF10095 36167-63-2 | Halofantrine hydrochloride C26H30Cl2F3NO.ClH
JF10031 6792-31-0 | Hexafluoropropene trimer C9F18
  • Prev
  • 1
  • 2
  • Next
Contact Us
Address

Joinhands Science Park No.4028 Nanhuan RD, Hangzhou ,310053 China

Tel

+86 0571-85586753

Email

sales@fluoropharm.com

About Us
  • Company Profile
  • Our Culture
  • Technology service
  • News
  • Contact Us
  • Web Sitemap
Latest News

FDA approves First repeatable drug gene Therapy, $630,000 a Year, for 'most painful diseases'

May 23, 2023

Wang Ben's team at Zhejiang University developed fluorine-containing polymer assembly drugs to achieve chemotherapeutic-immune cascade cancer therapy

Apr 24, 2023

The first patient administration of the new NASH drug, Kylo-0603, was completed in Phase I in China

Apr 10, 2023

Copyright © 2010-2023 Hangzhou Fluoro Pharmaceutical Co., Ltd. All rights reserved.